A
Agomab Therapeutics NV
AGMBCIK 0002020932NasdaqNon-AcceleratedEmerging GrowthBiological Products, (No Diagnostic Substances)C9BEFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-62.55M
Total Assets
$153.71M
Equity
—
Shares Out
34.17M
Op. Cash Flow
—
Business
Agomab Therapeutics NV is a foreign private issuer in Biological Products, (No Diagnostic Substances), headquartered in Belgium. Shares trade on Nasdaq under the ticker AGMB.
Auto-generated from company profile
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-62.55M |
| Total assets | $153.71M |
| Total liabilities | $22.80M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro